Summary
CVS Health Corporation (CVS) filed an 8-K on January 5, 2024, providing an update on its financial guidance and announcing executive changes. The company reaffirmed its full-year 2023 guidance for GAAP diluted EPS ($6.37-$6.61) and Adjusted EPS ($8.50-$8.70), expecting the latter to be in the upper half of the range. Full-year 2023 cash flow from operations guidance was also reaffirmed at the upper end of $12.5 billion to $13.5 billion. Looking ahead to 2024, CVS Health anticipates at least $7.26 in GAAP diluted EPS, at least $8.50 in Adjusted EPS, and at least $12.5 billion in cash flow from operations. The company also announced a $3.0 billion accelerated share repurchase transaction and projected at least 800,000 Medicare Advantage membership growth in 2024, driven by stronger-than-expected annual enrollment exceeding expectations.
Key Highlights
- 1Reaffirmed strong full-year 2023 financial guidance for EPS and cash flow from operations.
- 2Provided positive 2024 financial outlook with guidance for GAAP EPS, Adjusted EPS, and cash flow.
- 3Announced a significant $3.0 billion accelerated share repurchase program, indicating confidence in value.
- 4Projected robust Medicare Advantage membership growth of at least 800,000 in 2024, exceeding expectations.
- 5Appointed Thomas F. Cowhey as permanent Executive Vice President and Chief Financial Officer.
- 6Announced the departure of Shawn M. Guertin as CFO and President of Health Services due to family health reasons.
- 7Appointed Mike Pykosz as President of Health Care Delivery.